When does ONCOLYTICS BIOTECH INC (ONCY) report earnings?
ONCOLYTICS BIOTECH INC (ONCY) will report earnings on 2026-08-06.
ONCOLYTICS BIOTECH INC (ONCY) Forecast, Price Target & Analyst Ratings
NASDAQ:ONCY • CA6823108759
Current stock price
0.8701 USD
-0.01 (-1.12%)
At close:
0.888 USD
+0.02 (+2.06%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ONCOLYTICS BIOTECH INC (ONCY).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -CA$0.08
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.87 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.50%
ONCY was analyzed by 8 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about ONCY.
In the previous month the buy percentage consensus was at a similar level.
ONCY was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Lake Street | Initiate | Buy |
| 2025-05-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-16 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-03-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-10 | Maxim Group | Maintains | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-04 | Raymond James | Initiate | Outperform |
| 2024-03-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-23 | Canaccord Genuity | Reiterate | Buy -> Buy |
| 2023-06-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-24 | JonesTrading | Initiate | Buy |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 6, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -CA$0.08
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 22.56%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
ONCY is expected to report earnings on 8/6/2026. The consensus EPS estimate for the next earnings is -0.08 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 2,505.00% | N/A -33.98% | N/A 249.79% | N/A 155.79% | N/A 56.96% | N/A 55.71% | N/A | |||||||||||
| EBITDA YoY % growth | -14.32M | -14.96M -4.47% | -15.59M -4.21% | -17.17M -10.13% | -19.88M -15.78% | -25.01M -25.80% | -25.78M -3.08% | -26.53M -2.91% | -33.388M -25.85% | -34.558M -3.50% | N/A -81.49% | N/A -42.03% | N/A 64.74% | N/A -107.06% | N/A 42.91% | N/A 234.67% | N/A 180.05% | N/A -31.03% | N/A 102.28% | |
| EBIT YoY % growth | -14.5M | -15.12M -4.28% | -15.68M -3.70% | -17.27M -10.14% | -20.37M -17.95% | -25.46M -24.99% | -26.23M -3.02% | -26.92M -2.63% | -33.791M -25.52% | -34.982M -3.52% | N/A -22.07% | N/A -31.21% | N/A 28.43% | N/A -26.60% | N/A 116.00% | N/A 1,143.20% | N/A 207.17% | N/A 78.22% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -1.14 | N/A -13.62% | -1.14 11.99% | -1.04 9.21% | -0.93 10.14% | -0.43 53.76% | -0.49 -13.95% | -0.44 10.20% | -0.41 6.82% | -0.41 | N/A 21.99% | N/A -10.53% | N/A 22.86% | N/A 120.37% | N/A 2,098.73% | N/A 103.38% | N/A 51.28% | N/A 43.70% | N/A |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 22.56% | -0.10 -26.25% | -0.10 -44.29% | -0.10 27.90% | -0.08 -4.34% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -19.291M -140.75% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.583M -37.28% | -8.141M -16.31% | -8.495M -48.88% | -9.202M 15.88% | -9.557M 17.49% |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.11%
EPS Next 5 Year
37.86%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
5.76%
EBIT Next 5 Year
0.67%
ONCOLYTICS BIOTECH INC / ONCY Forecast FAQ
What are the consensus estimates for ONCOLYTICS BIOTECH INC (ONCY) next earnings?
The consensus EPS estimate for the next earnings of ONCOLYTICS BIOTECH INC (ONCY) is -0.08 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for ONCOLYTICS BIOTECH INC (ONCY) stock?
The consensus rating for ONCOLYTICS BIOTECH INC (ONCY) is 77.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.